INOVIQ Management

Management criteria checks 3/4

INOVIQ's CEO is Leearne Hinch, appointed in Nov 2016, has a tenure of 7.5 years. total yearly compensation is A$558.11K, comprised of 71% salary and 29% bonuses, including company stock and options. directly owns 0.081% of the company’s shares, worth A$36.80K. The average tenure of the management team and the board of directors is 3.7 years and 4.9 years respectively.

Key information

Leearne Hinch

Chief executive officer

AU$558.1k

Total compensation

CEO salary percentage	71.0%
CEO tenure	7.5yrs
CEO ownership	0.08%
Management average tenure	3.7yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Leearne Hinch's remuneration changed compared to INOVIQ's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$7m
Sep 30 2023	n/a	n/a	-AU$8m
Jun 30 2023	AU$558k	AU$396k	-AU$9m
Mar 31 2023	n/a	n/a	-AU$15m
Dec 31 2022	n/a	n/a	-AU$21m
Sep 30 2022	n/a	n/a	-AU$20m
Jun 30 2022	AU$485k	AU$376k	-AU$18m
Mar 31 2022	n/a	n/a	-AU$14m
Dec 31 2021	n/a	n/a	-AU$11m
Sep 30 2021	n/a	n/a	-AU$11m
Jun 30 2021	AU$867k	AU$330k	-AU$11m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$4m
Jun 30 2020	AU$712k	AU$330k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$2m
Sep 30 2019	n/a	n/a	-AU$2m
Jun 30 2019	AU$442k	AU$361k	-AU$2m
Mar 31 2019	n/a	n/a	-AU$2m
Dec 31 2018	n/a	n/a	-AU$2m
Sep 30 2018	n/a	n/a	-AU$2m
Jun 30 2018	AU$403k	AU$359k	-AU$2m
Mar 31 2018	n/a	n/a	-AU$2m
Dec 31 2017	n/a	n/a	-AU$2m
Sep 30 2017	n/a	n/a	-AU$2m
Jun 30 2017	AU$255k	AU$203k	-AU$3m

Compensation vs Market: Leearne's total compensation ($USD367.40K) is about average for companies of similar size in the Australian market ($USD294.64K).

Compensation vs Earnings: Leearne's compensation has increased whilst the company is unprofitable.

CEO

Leearne Hinch

7.5yrs

Tenure

AU$558,111

Compensation

Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of INOVIQ Ltd (formerly known as BARD1 Life Sciences Limited) since November 7, 2016. Dr. Hinch is a biotech...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Leearne Hinch	Chief Executive Officer	7.5yrs	AU$558.11k	0.081% A$ 36.8k
Mark Edwards	CFO & Company Secretary	1.5yrs	AU$203.37k	no data
Gregory Rice	Chief Scientific Officer	3.7yrs	AU$360.66k	0.022% A$ 9.9k

3.7yrs

Average Tenure

Experienced Management: IIQ's management team is considered experienced (3.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Philip Powell	Independent Non-Executive Director	4.9yrs	AU$106.55k	0.52% A$ 234.9k
David Williams	Non-Executive Chairman	less than a year	no data	5.43% A$ 2.5m
Geoffrey Cumming	Independent Non-Executive Director	3.8yrs	AU$134.18k	0.19% A$ 87.8k
Robert Johnston	Independent Non-Executive Director	4.9yrs	AU$106.55k	0.44% A$ 200.1k
Samuel Janes	Member of Advisory Board	6.8yrs	no data	no data

4.9yrs

Average Tenure

Experienced Board: IIQ's board of directors are considered experienced (4.9 years average tenure).

INOVIQ Management

Management criteria checks 3/4

Key information

Recent management updates

INOVIQ Ltd, Annual General Meeting, Nov 28, 2023

Insufficient new directors

INOVIQ Ltd Announces Resignation of Professor Allan Cripps AO as Director

INOVIQ Limited Announces Company Secretary Changes

INOVIQ Ltd, Annual General Meeting, Nov 28, 2022

High number of new directors

Recent updates

New major risk - Financial position

INOVIQ Ltd, Annual General Meeting, Nov 28, 2023

New major risk - Financial position

Full year 2023 earnings released: AU$0.097 loss per share (vs AU$0.20 loss in FY 2022)

New minor risk - Financial data availability

Insufficient new directors

Inoviq Limited Announces Clinical Validation Study for Subb2m/Ca15-3 Breast Cancer Test

First half 2023 earnings released: AU$6.70 loss per share (vs AU$0.031 loss in 1H 2022)

INOVIQ Limited Announces Positive Results for SubB2M Breast Cancer Test

INOVIQ Ltd Announces Resignation of Professor Allan Cripps AO as Director

INOVIQ Limited Announces Company Secretary Changes

INOVIQ Ltd, Annual General Meeting, Nov 28, 2022

Full year 2022 earnings released: AU$0.072 loss per share (vs AU$0.14 loss in FY 2021)

High number of new directors

INOVIQ Limited Announces Positive SubB2M IHC Results for Melanoma

High number of new and inexperienced directors

INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC

INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC

Inoviq Limited Announces Update on Legal Proceedings and Bard1 Autoantibody Program

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.14 loss per share (vs AU$0.072 loss in FY 2020)

Chief Scientific Officer Peter French has left the company

Chief Scientific Officer Peter French has left the company

BARD1 Life Sciences Limited Announces That Previously Reported Study Results for A Potential Bard1 Autoantibody Test for Early Detection of Ovarian Cancer in the International Peer-Reviewed Journal Genes

BARD1 Life Sciences Limited Announces SubB2M Breast Cancer Test Manuscript Submitted

Bard1 Life Sciences Limited Announces the Results of A Preliminary Study Which Demonstrates the Feasibility of Using Subb2m in an Ihc Application for Breast Cancer Tissue

BARD1 Life Sciences Limited Launches Its RUO EXO-NET Product

BARD1 Life Sciences Limited Presents BARD1 EXO-NET Exosome Data at ISEV2021 Conference

BARD1 Life Sciences Limited Announces Positive Results from the BARD1 autoantibody assay

BARD1 Life Sciences Limited Announces Positive Results Evaluation of EXO-NET in Pancreatic Cancer

BARD1 Life Sciences Limited Receives the Initial Purchase Order for AUD 80,000 from Mirax for hTERT

Bard1 Life Sciences Limited Gains Class II In-Vitro Diagnostic Medical Device Registration from South Korea's Ministry of Food and Drug Safety for the hTERT Test

Insider recently sold AU$8.2m worth of stock

BARD1 Life Sciences Limited Releases SUBB2M BREAST CANCER TEST DATA

Bard1 Life Sciences Limited Announces Outstanding SubB2M Ovarian Cancer Test Data

New 90-day low: AU$0.57

Dr. Irmgard Irminger-Finger Steps Down from Board of BARD1 Life Sciences Limited

New 90-day low: AU$0.60

BARD1 Life Sciences Limited Announces Resignation of Helen Fisher as Non-executive Director

BARD1 Life Sciences Limited Gains New High-Volume Customer for Its hTERT test

BARD1 Life Sciences Limited Announces the Successful Evaluation of the BARD1 kit

BARD1 Life Sciences Limited Auditor Raises 'Going Concern' Doubt

Earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure